Search
Searching Content indexed under Food and Drugs Law by Thomas N. Bulleit ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Podcast: IP(DC): Drug Prices, Political Pressures & Patents
That really ties the hands of plans trying to get lower prices because they can't exclude similar drugs just because they're expensive.
United States
22 Aug 2019
2
Trending Video: Drug Pricing Initiatives During The Trump Presidency (Video)
Tom Bulleit, Ropes & Gray health care partner, discusses the Trump Administration's latest drug pricing initiatives.
United States
28 Jun 2019
3
The Trump Administration's Latest Drug Pricing Initiatives
Donald Trump's election in 2016 placed pharmaceutical companies in uncharted territory. Unlike predecessors from both major political parties, Trump did not shy away from directly criticizing the industry.
United States
21 Jan 2019
4
A Closer Look At CMS' Drug Price Disclosure Proposal
One important difference between the standards is how strong the government's interest must be in order to justify the regulation.
United States
29 Oct 2018
5
A Look Inside Trump's 4-Point Plan For Curbing Drug Prices
On May 11, President Donald Trump outlined his administration's four-point plan for curbing prescription drug prices. With rare exceptions, the plan does nothing that will have immediate or even short-term effects, ...
United States
30 May 2018
6
Outlook 2017 Teleconference: Revisiting the Trump Administration's Impact on Life Sciences and Health Care—the First 100 Days
On Tuesday, May 2, Ropes & Gray hosted a teleconference, "Outlook 2017 Teleconference: Revisiting the Trump Administration's Impact on Life Sciences and Health Care – the First 100 Days," on the potential regulatory and compliance impact of the Trump Administration on life sciences and health care companies.
United States
24 May 2017
7
Outlook 2017 for Health Care and Life Sciences—What to Expect from HHS, FDA and Congress (podcast)
What impact will the incoming Trump administration have on the 2017 health care and life sciences regulatory outlook?
United States
29 Dec 2016
Links to Result pages
 
1